Rosacea Market Insights, Epidemiology and Market Forecast-2030

Albany, NY -- (SBWire) -- 06/24/2020 --Rosacea Market Insights, Epidemiology and Market Forecast-2030

(Albany, US) DelveInsight launched a new report on Rosacea Market Insights, Epidemiology and Market Forecast-2030

Some of the key facts of the report
1. The total prevalent population of Rosacea in the 7MM was 47,634,256 in 2017.
2. The prevalence of Rosacea was found in the United States with 16,652,170 cases in 2017.
3. Germany had a prevalent population of Rosacea with 8,383,943 cases in 2017.
4. France had Rosacea prevalent population of 6,082,002 cases in 2017.
5. Italy had a prevalent population of Rosacea with 3,217,083 cases in 2017.

Key benefits of the report
1. Rosacea market report covers a descriptive overview and comprehensive insight of the Rosacea epidemiology and Rosacea market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Rosacea market report provides insights into the current and emerging therapies.
3. Rosacea market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Rosacea market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rosacea market.

Request for sample pages

"Rosacea prevalence is high in females than in males".

The current Rosacea therapeutic landscape can be divided into four major categories based on the route of administration and the approved usage for the condition. These are topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids.

Among Topical therapies, topical retinoids mainly include Tretinoin, Tazarotene, Adapalene, and Clindamycin/tretinoin, and several others are used to reduce erythema, papules and pustules, and telangiectasias. Among these, Tretinoin has the lowest cost and most commonly prescribed topical retinoid, accounting for the majority of the population.

Topical antibiotics, such as metronidazole (e.g. Metrolotion), clindamycin, erythromycin, azelaic acid (e.g. Fincea), benzoyl peroxide, benzoyl peroxide/clindamycin, benzoyl peroxide/erythromycin, sulfacetamide, and sulfacetamide/sulfur, are applied directly to the skin to kill bacteria on the surface of the skin.

Topical antibiotics are the most commonly prescribed class of drug for all sexes and age groups. The most common topical antibiotics prescribed are metronidazole (for an estimated half of the population of topical antibiotics) followed by clindamycin, erythromycin, and azelaic acid.

The launch of the emerging therapies is expected to significantly impact Rosacea treatment scenario in the upcoming years:-
Drugs covered
- FMX103
- Epsolay
- ACU-D1
- HY01
- AFX-4031
- AOB103
And many others

The key players in the Rosacea market are:
- Foamix Pharmaceuticals
- Sol-Gel
- Accuitis
- Hovione Scientia Limited
- Afecta Pharmaceuticals
- AOBiome
And many others

Table of contents
1. Key Insights
2 Executive Summary of Rosacea
3. Rosacea Market Overview at a Glance
4. Rosacea Disease Background and Overview: Rosacea
5. Rosacea Epidemiology and Patient Population
6. Country Wise-Epidemiology of Rosacea Disease
6.1. United States
6.2. EU5 Countries
6.2.1. Germany
6.2.2. France
6.2.3. Italy
6.2.4. Spain
6.2.5. United Kingdom
6.3. Japan
7. Rosacea Treatment Algorithm, Current Treatment, and Medical Practices
8. Unmet Needs
9. Rosacea Marketed Drugs
9.1. Rhofade: Allergan
9.2. Oracea: Galderma Laboratories (Nestle Skin Health)
9.3. Mirvaso: Galderma Laboratories (Nestle Skin Health)
9.4. Finacea: Bayer
9.5. Soolantra: Galderma Laboratories, Inc. (Nestle Skin Health)
9.6. Metrogel: Galderma Laboratories (Nestle Skin Health)
10. Key Cross Competition
11. Rosacea Emerging Drugs
11.1. FMX103: Foamix Pharmaceuticals
11.2. Epsolay: Sol-Gel
11.3. ACU-D1: Accuitis
11.4. HY01: Hovione Scientia Limited
11.5. AFX-4031: Afecta Pharmaceuticals
11.6. AOB103: AOBiome
12. Rosacea 7 Major Market Analysis
13. The United States Market Outlook
14. EU-5 Countries: Market Outlook
14.1. Germany
14.2. France
14.3. Italy
14.4. Spain
14.5. United Kingdom
15. Japan: Market Outlook
16. Access and Reimbursement Overview of Rosacea
17. Rosacea Market Drivers
18. Rosacea Market Barriers
19. SWOT Analysis
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
info@delveinsight.com
+919650213330
SOURCE DelveInsight